CLINICAL TRIALS PROFILE FOR LOTILANER
✉ Email this page to a colleague
All Clinical Trials for LOTILANER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05387083 ↗ | A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 | Not yet recruiting | Tarsus Pharmaceuticals, Inc. | Phase 2 | 2022-07-29 | This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin. |
| NCT05629390 ↗ | Phase III Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study | Recruiting | LianBio LLC | Phase 3 | 2022-10-23 | The Phase III main study is a randomized, controlled, multicenter, double-masked, parallel trial to evaluate the efficacy and safety of 0.25% TP-03, for the treatment of Demodex blepharitis in China. The PK sub-study is a single-arm, open-label trial to evaluate systemic Lotilaner PK of 0.25% TP-03 in whole blood following topical ocular administration |
| NCT05838170 ↗ | Study of TP-04 in Participants With Papulopustular Rosacea | Recruiting | Tarsus Pharmaceuticals, Inc. | Phase 2 | 2023-03-01 | This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTILANER
Condition Name
Clinical Trial Locations for LOTILANER
Clinical Trial Progress for LOTILANER
Clinical Trial Phase
Clinical Trial Sponsors for LOTILANER
Sponsor Name
